On November 26, 2018, IRESSEF had the honor and the pleasure of welcoming Professor Salim Safurdeen Abdool Karim.
Teacher. Salim Abdool Karim is a South African epidemiologist and infectious disease specialist. He is widely recognized for his contributions to research on HIV prevention and treatment. He is Director of CAPRISA and Vice-Chancellor of the University of KwaZulu-Natal in Durban, South Africa. He is also Professor of Clinical Epidemiology at the Mailman School of Public Health at Columbia University, Adjunct Professor of Medicine at Weill Medical College, Cornell University, New York, and Associate Member of the Ragon Institute at Massachusetts General Hospital, Massachusetts. Institute of Technology (MIT) and Harvard University. Prof. Abdool Karim is a member of the WHO Expert Advisory Group on STIs and HIV, a member of the PEPFAR Scientific Advisory Board and a member of the Global HIV Vaccine Enterprise Strategic Advisory Board.
His contributions to microbicides for HIV prevention span two decades, including the tenofovir gel CAPRISA 004 trial, which has proven beyond doubt that antiretrovirals can prevent HIV and HIV infection. herpes simplex type 2 in women.
As a co-inventor of the patent, he participated in the development of clade C HIV vaccines and then led the first trial of HIV vaccine in South Africa. His clinical research on the treatment of tuberculosis and HIV has influenced the clinical management of co-infected patients and continues to educate him.
According to him, IRESSEF has to identify and define its research priorities like CAPRISA which has set itself the objective of answering two questions.
One is to help limit or stop HIV transmission and the other to reduce HIV-related deaths.